BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CKD-703 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CKD-703\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07439094-2430@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:CKD-703: Phase 1/2 readout est. (NCT07439094)
DESCRIPTION:CKD-703\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Fir
 st-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell L
 ung Cancer\nEstimated primary completion: December 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/ckd-703#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07439094
URL:https://assetmemo.bio/drug/ckd-703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
